FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019652024> ?p ?o ?g. }

• W2019652024 endingPage "298" @default.
• W2019652024 startingPage "286" @default.
• W2019652024 abstract "Like itraconazole and ketoconazole, posaconazole, a broad-spectrum oral triazole antifungal, inhibits the activity of the cytochrome P450 (CYP) isozyme 3A4. Midazolam, a short-acting benzodiazepine, is metabolized by CYP3A4. Potential drug interactions can be expected in patients who are concurrently receiving inhibitors and substrates of CYP3A4 (eg, ketoconazole, posaconazole) and benzodiazepines (eg, midazolam). Because of the potential for drug interactions, it is important to determine the effects of posaconazole on the pharmacokinetic properties of midazolam.The aim of this study was to compare the effects of oral administration of posaconazole versus ketoconazole on the pharmacokinetic properties of orally and intravenously administered midazolam.This Phase I, randomized, open-label, crossover study was conducted at Swiss Pharma Contract Ltd., Allschwil, Switzerland. Healthy volunteers were randomly assigned to 1 of 2 treatment arms. Arm 1 received posaconazole 200 mg BID for 7 days, posaconazole 400 mg BID for 7 days, no drugs during a 28-day washout, and ketoconazole 400 mg once daily for 7 days. Arm 2 received posaconazole and ketoconazole in the reverse order, with a 28-day washout between treatments. An oral/IV midazolam sequence (oral midazolam 2 mg and IV midazolam 0.4 mg) was administered on days -2/-1, 6/7, 13/14 (arm 1), 36/17 (arm 2), 43/44, and 50/51 in both treatment arms. Blood samples were collected up to 24 hours after midazolam administration. Pharmacokinetic parameters, including C(max), C(min) (before azole administration), terminal-phase t(1/2) (t(1/2z)), and AUC to final measurable sampling time (AUC(tf)), were calculated using noncompartmental methods, and drug interactions were evaluated using analysis of variance. Adverse events were collected using physical examination, including vital sign measurements; clinical laboratory analysis; electrocardiography; and direct questioning at predefined time points throughout the study to assess tolerability.A total of 12 subjects were enrolled (11 men, 1 woman; all white; mean age, 42.8 years [range, 28-53 years]; mean weight, 80.6 kg; and mean body mass index, 25.6 kg/m(2)). All of the subjects completed the study. Based on point estimates of logarithm-transformed data, posaconazole 200 and 400 mg BID were associated with significant increases in midazolam C(max) (up to 1.3- and 2.4-fold) and AUC(tf) values (up to 4.6- and 6.2-fold), respectively. Ketoconazole 400 mg once daily was associated with significantly increased midazolam C(max) and AUC(tf) (up to 2.8- and 8.2-fold, respectively). When midazolam was concurrently administered with either azole, t(1/2z) was prolonged. Seven of 12 (58%) subjects reported > or =1 adverse event during the study (5 with posaconazole alone and 4 with posaconazole + midazolam). The most common adverse events were diarrhea (3 subjects [25%] with posaconazole alone, 2 [17%] with ketoconazole alone, and 1 [8%] with posaconazole + midazolam) and flatulence (1 [8%] with posaconazole alone and 1 [8%] with midazolam alone).The results from this study in a small, all-white population of healthy volunteers suggest that posaconazole was a potent inhibitor of CYP3A4, but to a lesser extent than was ketoconazole. Monitoring patients for adverse events, the need for dose adjustments, or both during coadministration with posaconazole may be warranted in patients being treated with benzodiazepines that are predominantly metabolized through CYP3A4 (eg, midazolam)." @default.
• W2019652024 created "2016-06-24" @default.
• W2019652024 creator A5004765077 @default.
• W2019652024 creator A5021510186 @default.
• W2019652024 creator A5041620286 @default.
• W2019652024 creator A5044662094 @default.
• W2019652024 creator A5052635590 @default.
• W2019652024 creator A5067040413 @default.
• W2019652024 creator A5083897514 @default.
• W2019652024 date "2009-02-01" @default.
• W2019652024 modified "2023-10-14" @default.
• W2019652024 title "Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers" @default.
• W2019652024 cites W1504403745 @default.
• W2019652024 cites W1974821515 @default.
• W2019652024 cites W1988385266 @default.
• W2019652024 cites W1989345554 @default.
• W2019652024 cites W1992985546 @default.
• W2019652024 cites W2032771458 @default.
• W2019652024 cites W2054040800 @default.
• W2019652024 cites W2080129180 @default.
• W2019652024 cites W2106243271 @default.
• W2019652024 cites W2119544769 @default.
• W2019652024 cites W2124596533 @default.
• W2019652024 cites W2127288395 @default.
• W2019652024 cites W2133496791 @default.
• W2019652024 cites W2139126851 @default.
• W2019652024 cites W2142619354 @default.
• W2019652024 cites W2142996250 @default.
• W2019652024 cites W2157856480 @default.
• W2019652024 cites W4241401467 @default.
• W2019652024 cites W4323284006 @default.
• W2019652024 doi "https://doi.org/10.1016/j.clinthera.2009.02.022" @default.
• W2019652024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19302901" @default.
• W2019652024 hasPublicationYear "2009" @default.
• W2019652024 type Work @default.
• W2019652024 sameAs 2019652024 @default.
• W2019652024 citedByCount "55" @default.
• W2019652024 countsByYear W20196520242012 @default.
• W2019652024 countsByYear W20196520242013 @default.
• W2019652024 countsByYear W20196520242014 @default.
• W2019652024 countsByYear W20196520242015 @default.
• W2019652024 countsByYear W20196520242016 @default.
• W2019652024 countsByYear W20196520242017 @default.
• W2019652024 countsByYear W20196520242018 @default.
• W2019652024 countsByYear W20196520242020 @default.
• W2019652024 countsByYear W20196520242021 @default.
• W2019652024 countsByYear W20196520242022 @default.
• W2019652024 countsByYear W20196520242023 @default.
• W2019652024 crossrefType "journal-article" @default.
• W2019652024 hasAuthorship W2019652024A5004765077 @default.
• W2019652024 hasAuthorship W2019652024A5021510186 @default.
• W2019652024 hasAuthorship W2019652024A5041620286 @default.
• W2019652024 hasAuthorship W2019652024A5044662094 @default.
• W2019652024 hasAuthorship W2019652024A5052635590 @default.
• W2019652024 hasAuthorship W2019652024A5067040413 @default.
• W2019652024 hasAuthorship W2019652024A5083897514 @default.
• W2019652024 hasConcept C109650736 @default.
• W2019652024 hasConcept C112705442 @default.
• W2019652024 hasConcept C126322002 @default.
• W2019652024 hasConcept C142724271 @default.
• W2019652024 hasConcept C16005928 @default.
• W2019652024 hasConcept C204787440 @default.
• W2019652024 hasConcept C27081682 @default.
• W2019652024 hasConcept C2776814716 @default.
• W2019652024 hasConcept C2777056448 @default.
• W2019652024 hasConcept C2777071850 @default.
• W2019652024 hasConcept C2778000748 @default.
• W2019652024 hasConcept C2778566413 @default.
• W2019652024 hasConcept C2779548794 @default.
• W2019652024 hasConcept C2781064554 @default.
• W2019652024 hasConcept C42219234 @default.
• W2019652024 hasConcept C526171541 @default.
• W2019652024 hasConcept C62231903 @default.
• W2019652024 hasConcept C71924100 @default.
• W2019652024 hasConcept C87813604 @default.
• W2019652024 hasConcept C97320921 @default.
• W2019652024 hasConcept C98274493 @default.
• W2019652024 hasConceptScore W2019652024C109650736 @default.
• W2019652024 hasConceptScore W2019652024C112705442 @default.
• W2019652024 hasConceptScore W2019652024C126322002 @default.
• W2019652024 hasConceptScore W2019652024C142724271 @default.
• W2019652024 hasConceptScore W2019652024C16005928 @default.
• W2019652024 hasConceptScore W2019652024C204787440 @default.
• W2019652024 hasConceptScore W2019652024C27081682 @default.
• W2019652024 hasConceptScore W2019652024C2776814716 @default.
• W2019652024 hasConceptScore W2019652024C2777056448 @default.
• W2019652024 hasConceptScore W2019652024C2777071850 @default.
• W2019652024 hasConceptScore W2019652024C2778000748 @default.
• W2019652024 hasConceptScore W2019652024C2778566413 @default.
• W2019652024 hasConceptScore W2019652024C2779548794 @default.
• W2019652024 hasConceptScore W2019652024C2781064554 @default.
• W2019652024 hasConceptScore W2019652024C42219234 @default.
• W2019652024 hasConceptScore W2019652024C526171541 @default.
• W2019652024 hasConceptScore W2019652024C62231903 @default.
• W2019652024 hasConceptScore W2019652024C71924100 @default.
• W2019652024 hasConceptScore W2019652024C87813604 @default.
• W2019652024 hasConceptScore W2019652024C97320921 @default.
• W2019652024 hasConceptScore W2019652024C98274493 @default.

• next